Deposition characteristics of a new allergic rhinitis nasal spray (MP29‐02*) in an anatomical model of the human nasal cavity

Alex D'Addio,Michael Mayer,Claus Bachert,Nancy Ruiz,Ruth Murray

doi:10.1186/2045-7022-5-s4-p40

Alex D'Addio, Michael Mayer + Show 3 more

Open Access

https://doi.org/10.1186/2045-7022-5-s4-p40

Copy DOI

Abstract

Background Intranasal sprays must be delivered to the nasal cavity in sufficient volume, appropriate viscosity and droplet size and with a technique that allows optimal retention, maximizes absorption from the mucosa, and the potential for maximum therapeutic effect. The aim of this study was to evaluate nasal drug run-off after administration of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) with sequential administration of marketed AZE and FP nasal sprays in vitro.

Highlights

Intranasal sprays must be delivered to the nasal cavity in sufficient volume, appropriate viscosity and droplet size and with a technique that allows optimal retention, maximizes absorption from the mucosa, and the potential for maximum therapeutic effect
Three replicates of sequential sprays of AZE followed 1 min later by either branded or generic FP showed significant anterior nasal drip from the nostril and toward the back of the nasal cavity; AZE & branded FP: anterior spray area = 1.67 – 3.16 cm2; AZE & generic FP: anterior spray area: 0.68 – 1.83 cm2
The delivery of MP29-02* showed improved retention in the targeted areas compared to sequential administration of marketed intranasal monoproducts

Summary

Introduction

Intranasal sprays must be delivered to the nasal cavity in sufficient volume, appropriate viscosity and droplet size and with a technique that allows optimal retention, maximizes absorption from the mucosa, and the potential for maximum therapeutic effect. The aim of this study was to evaluate nasal drug run-off after administration of MP29-02* (a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in an advanced delivery system) with sequential administration of marketed AZE and FP nasal sprays in vitro

Objectives

Results

Conclusion